NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Overview Fund Activity
Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

25 hedge funds and large institutions have $383K invested in Navidea Biopharmaceuticals Inc. in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.

Holders
25
Holders Change
-1
Holders Change %
-3.85%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
4
Closed
4
Calls
$14K
Puts
$52K
Net Calls
-$38K
Net Calls Change
+$156K

Top Buyers

1
Millennium Management
1
Millennium Management
New York
$10K
2
VF
2
Virtu Financial
New York
$10K
3
Renaissance Technologies
3
Renaissance Technologies
New York
$7K
4
Hudson Bay Capital Management
4
Hudson Bay Capital Management
Connecticut
$3K
5
PFO
5
Pathstone Family Office
New Jersey
$5.54K

Top Sellers

1
Citadel Advisors
1
Citadel Advisors
Florida
$0
2
TSS
2
Two Sigma Securities
New York
$0
3
Group One Trading
3
Group One Trading
Illinois
$48K
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$181K
5
Simplex Trading
5
Simplex Trading
Illinois
$4K
Name Market Value Shares Shares
Change 		Shares
Change %
JPMorgan Chase & Co
26
JPMorgan Chase & Co
New York
$0 1,050 – –
CFGS
27
Concourse Financial Group Securities
Alabama
– – – –
Morgan Stanley
28
Morgan Stanley
New York
$0 266 – –
HT
29
HAP Trading
New York
– – – –
UBS Group
30
UBS Group
Switzerland
$0 105 – –
PA
31
Parallel Advisors
California
$0 350 – –
1
2